Trials / Completed
CompletedNCT02120950
Aflibercept in Polypoidal Choroidal Vasculopathy
A Randomized, Double-masked, Sham-controlled Phase 3b/4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy as Indicated in Subjects With Polypoidal Choroidal Vasculopathy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 333 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Eylea is administered as an intravitreal injection |
| OTHER | Visudyne | Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser) |
Timeline
- Start date
- 2014-05-29
- Primary completion
- 2016-08-12
- Completion
- 2017-07-07
- First posted
- 2014-04-23
- Last updated
- 2020-12-02
- Results posted
- 2019-01-15
Locations
62 sites across 8 countries: Australia, Germany, Hong Kong, Hungary, Japan, Singapore, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT02120950. Inclusion in this directory is not an endorsement.